Luis Borges has sold IPSC and made no open-market buys since Mar 2023

Dr. Luis Borges is a distinguished biotechnology executive with over 28 years of scientific and executive leadership experience in both large and emerging biotech companies( He earned his Ph.D. in Pathology from the University of Washington School of Medicine( and is recognized as an expert in iPSC-derived T and NK cell therapies( Throughout his career, he has held prominent positions including Chief Scientific Officer at Century Therapeutics, where he led the preclinical development of multiple iPSC-derived therapies and advanced the company's first product candidate, CNTY-101, into Phase I clinical trials for non-Hodgkin lymphoma and autoimmune diseases( His tenure at Century was followed by roles as Chief Scientific Officer at Metagenomi and Cell Medica, Senior Vice President of Research at Five Prime Therapeutics, and Scientific Director in Amgen's Hematology and Oncology division(

Dr. Borges has demonstrated a consistent track record of advancing innovative therapies from discovery through clinical development while driving scientific and operational excellence( His expertise spans both discovery research and translational science, with experience helping advance multiple drug development candidates through IND filing into clinical development and FDA approval( Beyond his executive roles, he has contributed to the scientific community through appointments to prestigious scientific advisory boards and continues to be sought after for leadership positions in cell therapy development, reflecting his standing as a key figure in the biotechnology industry(

Written by Perplexity from public sources.